Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Accumulated Expenses (2016 - 2019)

Bristol Myers Squibb (BMYMP) has disclosed Accumulated Expenses for 11 consecutive years, with $5.9 billion as the latest value for Q1 2019.

  • Quarterly Accumulated Expenses rose 5.3% to $5.9 billion in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $5.9 billion through Mar 2019, up 5.3% year-over-year, with the annual reading at $6.5 billion for FY2018, 7.9% up from the prior year.
  • Accumulated Expenses for Q1 2019 was $5.9 billion at Bristol Myers Squibb, down from $6.5 billion in the prior quarter.
  • The five-year high for Accumulated Expenses was $6.5 billion in Q4 2018, with the low at $1.8 billion in Q1 2015.
  • Average Accumulated Expenses over 5 years is $4.8 billion, with a median of $5.1 billion recorded in 2017.
  • The sharpest move saw Accumulated Expenses dropped 10.32% in 2015, then soared 140.7% in 2016.
  • Over 5 years, Accumulated Expenses stood at $4.7 billion in 2015, then increased by 11.25% to $5.3 billion in 2016, then increased by 14.1% to $6.0 billion in 2017, then rose by 7.9% to $6.5 billion in 2018, then decreased by 9.75% to $5.9 billion in 2019.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $5.9 billion, $6.5 billion, and $5.9 billion for Q1 2019, Q4 2018, and Q3 2018 respectively.